OTHER GROUP COMPANIES
- Login to Trade
- Login to DP
- Karvy Customer
-
OTHER GROUP COMPANIES
-
- Home
Metropolis Healthcare reported 30% fall in consolidated net profit to Rs 41.2 crore despite a 7% rise in total revenue from operations to Rs 293.1 crore in Q3 FY22 over Q3 FY21.
Reported EBIDTA in Q3 FY22 was Rs 76.2 crore, down by 12% from Rs 86.7 crore in Q3 FY21. Reported EBIDTA Margin was 26% in Q3 FY22 as against 31.5% in Q3 FY21.
Ameera Shah, promoter and managing director, Metropolis Healthcare said: ??During Q3FY22, we are pleased to share that we have been able to grow our non-covid revenue despite sharp drop in volumes from a government contract. We have made increased investments in digital& marketing, manpower& customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a short term phenomenon.
Our focused cities performance and B2C contribution continues to witness healthy growth and is a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers.
We have also been able to successfully complete the acquisition of Hitech Diagnostics during Q3 which will enable us to scale up our business, improve the B2C revenue contribution and tap the value end of the market.?
The company said its board has declared an interim dividend of Rs 8 per share for the financial year 2021-22.
Metropolis Healthcare is a leading diagnostics company in India with a widespread presence across 20 states in India. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities.
The scrip fell 1.63% to Rs 2419.95 on the BSE.
Powered by Capital Market - Live News
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
Aug 12, 2022
The laws of the financial world are different from the physical world. You can have prolonged periods of time, when sanity takes a back seat and excesses happen.
R. Venkataraman Aug 20, 2021
Retail trading or day trading has exploded because of falling brokerage rates, democratization of information, higher transparency and mobile platforms.
R. Venkataraman Jun 15, 2021
My simple message for dear readers is, if you don’t have any desperate need for funds, then don’t do anything.
R. Venkataraman May 12, 2021
The blow up of a US hedge fund has resulted in WhatsApp university offering many courses on what went wrong with Bill Hwang and Archegos.
R. Venkataraman Apr 09, 2021
The expensive valuations have been sustained by strong rebound in corporate earnings which led to ~8% upgrade in FY22 Nifty EPS since October 2020.
R. Venkataraman Mar 26, 2021
We believe the interest rates are likely to have bottomed due to inflationary pressure, large government borrowings and normalizing credit growth. Hence rate sensitive sectors should be avoided in our view.
R. Venkataraman Feb 17, 2021
As markets make new highs, one gets more emails and messages, which highlight the accomplishments of traders who have found a formula for making money.
R. Venkataraman Jan 27, 2021
Data does not seem to convincingly prove that short periods of high returns are always followed by meagre returns. Only in 4 instances, we had negative returns in the subsequent year.
R. Venkataraman Jan 01, 2021
Since September end, Bankex is up 16% with large banks like ICICI Bank, Bandhan up 20-27%, Housing Finance Companies like Repco, LICHF, PNB Housing are up 50%-100% from their six-month lows.
R. Venkataraman Oct 13, 2020
Morgan Housel’s 'The Psychology of Money' explains in detail the role of human biases in investment decisions.
R. Venkataraman Sep 26, 2020
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity
